Literature DB >> 1825098

Hypertrophy, fibrosis and diastolic dysfunction in early canine experimental hypertension.

P S Douglas1, B Tallant.   

Abstract

To examine the relations among hypertrophy, fibrosis and diastolic performance in early experimental hypertension, 18 control dogs and 12 dogs with experimental left ventricular hypertrophy were studied. Diastolic function was impaired in dogs with left ventricular hypertrophy, with decreased Doppler early to atrial inflow velocity ratio (E/A) (1.35 versus 1.72), increased atrial filling fraction (35% versus 29%), decreased sonomicrometric peak rates of wall thinning (-2.01 versus -3.37 liters/s) and filling (4.33 versus 6.64 liters/s) and prolonged time constant of isovolumetric relaxation (tau; 34.3 versus 28.1 ms). Neither chamber stiffness (k; P = AekV) nor passive elastic stiffness (E; E = k sigma, where sigma = stress) was increased. At postmortem examination, the hypertensive left ventricle weighed significantly more than normal (116 versus 80 g; p less than 0.01) and had greater muscle fiber diameter at endocardial and epicardial sampling sites in the apical free wall, basal free wall and septum (mean diameter 50 +/- 8 microns in hypertensive dogs, 37 +/- 8 microns in normal dogs; p less than 0.01). In contrast, neither percent fibrosis (1.2 +/- 0.8 versus 0.9 +/- 0.6 in normal dogs) nor fibrotic volume (1.21 +/- 0.63 versus 0.72 +/- 0.42%/g in normal dogs) was significantly increased. Peak volumetric filling rate was inversely related to fiber diameter (r = -0.74, p less than 0.001), although no variable of left ventricular function was significantly related to percent or volume fibrosis (all r less than 0.60, all p greater than 0.05). Thus, diastolic dysfunction may exist in the setting of hypertrophy without significant fibrosis. Increased myocyte size was associated with early diastolic filling abnormalities characteristic of the hypertensive left ventricle. Fibrosis appears to be a less important determinant of diastolic performance.

Entities:  

Mesh:

Year:  1991        PMID: 1825098     DOI: 10.1016/s0735-1097(10)80127-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

Authors:  M Asif; J Egan; S Vasan; G N Jyothirmayi; M R Masurekar; S Lopez; C Williams; R L Torres; D Wagle; P Ulrich; A Cerami; M Brines; T J Regan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Relaxation in hypertrophic cardiomyopathy and hypertensive heart disease: relations between hypertrophy and diastolic function.

Authors:  S F De Marchi; Y Allemann; C Seiler
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

Review 3.  Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes.

Authors:  Alison J Kriegel; Melanie Gartz; Muhammad Z Afzal; Willem J de Lange; J Carter Ralphe; Jennifer L Strande
Journal:  J Cardiovasc Transl Res       Date:  2016-12-28       Impact factor: 4.132

Review 4.  Diastolic function in hypertension.

Authors:  R A Phillips; J A Diamond
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 5.  Metabolic regulation of in vivo myocardial contractile function: multiparameter analysis.

Authors:  M D Osbakken
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

6.  Topoisomerase 2B Decrease Results in Diastolic Dysfunction via p53 and Akt: A Novel Pathway.

Authors:  Rohit Moudgil; Gursharan Samra; Kyung Ae Ko; Hang Thi Vu; Tamlyn N Thomas; Weijia Luo; Jiang Chang; Anilkumar K Reddy; Keigi Fujiwara; Jun-Ichi Abe
Journal:  Front Cardiovasc Med       Date:  2020-11-06

7.  Right ventricular systolic and diastolic function assessed by two-dimensional speckle tracking echocardiography in dogs with myxomatous mitral valve disease.

Authors:  Yunosuke Yuchi; Ryohei Suzuki; Takahiro Teshima; Hirotaka Matsumoto; Hidekazu Koyama
Journal:  J Vet Med Sci       Date:  2021-11-04       Impact factor: 1.267

Review 8.  The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.

Authors:  Jay M Edelberg; Amy J Sehnert; Matthew E Mealiffe; Carlos L Del Rio; Robert McDowell
Journal:  Am J Cardiovasc Drugs       Date:  2022-04-18       Impact factor: 3.283

9.  The Association of Left Ventricular Hypertrophy with Intraventricular Dyssynchrony at Rest and during Exercise in Hypertensive Patients.

Authors:  Hye-Sun Seo; Youn-Haeng Cho; Jae Huk Choi; Jon Suh; Nae-Hee Lee; Oh Kyung Lim
Journal:  J Cardiovasc Ultrasound       Date:  2012-12-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.